ESMO

ESMO 2023: Highlights on sotorasib plus panitumumab in KRAS G12C-mutated mCRC: The CodeBreak 300 study

By ONA Editor October 23, 2023 No Comments

About Author

ONA Editor

The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.

About Author

Related Posts

For colon cancer that no longer responds to treatment, a new drug combination offers hope

Breakthrough combination therapy tackles drug resistance in lung cancer with common KRAS mutation

FDA approves sotorasib with panitumumab for KRAS G12C-mutated colorectal cancer

Leave A Reply Cancel Reply